• 생명과학회지
• /
• 제17권8호통권88호
• /
• pp.1075-1081
• /
• 2007

본 연구의 목적은 1) 캡사이신 섭취 (100 mg) 가 에너지 대사 조절자로서 열발생 교감신경활동과 관련된 자율신경활동을 향상시키는지, 2) 본 연구의 대상자들의 UCP1 과 ${\beta}_{3}$-AR 유전자 다양성이 자율신경활동에 영향을 주는지를 조사한 것이다. 8명의 대상자 (24.7 ${\pm}$ 1.8 세) 가 이 실험에 자발적으로 참여하였다. 심박수변이성 파워 스펙트랄 분석에 의해 평가된 심장자율신경활동과 에너지 대사는 총 90분간 매 30분마다 5분간 측정하였으며, 캡사이신 또는 위약 그룹은 무작위로 대상자에서 섭취되었다. 본 연구의 결과에서, 두 그룹간의 안정시 심박수에서는 유의한 차이가 없었다. 자율신경활동은 캡사이신 그룹에서 증가하였으나, 통계적으로 유의한 차이는 없었다. 총 대상자중, UCP1의 GG유전자 타입을 가진 대상자는 37.5% 였다. 그러나 캡사이신 그룹은 Test3에서 측정시 호흡 교환율이 유의하게 낮았다 (CAP: 0.80 ${\pm}$ 0.02 vs. CON: 0.85 ${\pm}$ 0.02, means ${\pm}$ SE, p<0.05). 이상의 결과로서, 캡사이신 (100 mg) 의 섭취는 지방분해를 향상시킴으로서 비만 과/또는 고지혈증을 가진 개개인에서 유익한 성분임을 시사할 수 있다. 또한 자율신경에 대한 비만과 관련된 UCP1 과/또는 ${\beta}_{3}$-AR 과 같은 유전자 다양성은 앞으로의 연구에 고려되어져야 할 것이다.

• 한국식품영양과학회지
• /
• 제45권4호
• /
• pp.484-491
• /
• 2016

본 연구에서는 시네트롤(Sinetrol-XPur)을 유전성 비만 마우스(Obese)에 7주간 식이 투여하여 항비만 효과를 알아보고자 하였다. 시네트롤을 섭취한 유전성 비만 마우스군(Sinetrol low와 Sinetrol high)의 체중증가량은 Obese군에 비하여 유의적으로 감소하였고, 간 무게변화량은 Sinetrol high군에서 Obese군보다 유의적으로 감소하였다. 백색지방의 무게변화량은 Sinetrol high군에서 Obese군보다 유의적으로 감소하였음을 확인하였다. 실험동물의 혈청 지질 함량은 TC, TG, LDL/VLDL-콜레스테롤이 Obese군에 비해 Sinetrol군에서 감소하였고, HDL-콜레스테롤은 유전성 비만군(Obese, Sinetrol low, Sinetrol high) 간에 유의적인 차이가 나타나지 않았다. HDL/LDL ratio를 계산한 결과에서는 Sinetrol군에서 Obese군보다 유의적으로 증가하였음을 확인하였다. 실험동물군의 지방조직에서 비만 관련 유전자들의 발현을 측정한 결과, FAS와 LPL의 발현은 Obese군보다 Sinetrol군에서 감소하였고 HSL의 발현은 유의적인 차이가 나타나지 않았지만, UCP-2의 발현은 Obese군에 비해 Sinetrol high군에서 유의적으로 증가하였음을 확인하였다. 또한 세포 내 cAMP를 측정한 결과 시네트롤 처리 시 농도 의존적으로 cAMP가 증가하였음을 확인하였고, 증가한 cAMP에 의해 UCP-2의 발현이 증가되는 것을 확인하였다. 이러한 결과로부터 시네트롤이 지방 합성과 관련된 유전자 발현의 억제 및 에너지 소비와 관련된 유전자의 발현을 증가시키고 체내 지방의 축적이나 합성을 감소시켜 체중의 증가를 예방하며, 혈중 지질 함량들을 개선하여 항비만 효과가 있는 천연 기능성 식품으로 활용할 수 있을 것으로 기대할 수 있다.

• 무역상무연구
• /
• 제12권
• /
• pp.519-551
• /
• 1999

When an issuing bank issues a documentary credit, it must decide if the reimbursement will be a direct or simple or a bank-to-bank reimbursement. This decision is based on the bank that is nominated to pay, incur a deferred payment undertaking, accept drafts or negotiate. If an issuing bank decided bank-to-bank reimbursement, it must include the information in the credit instructing the nominated bank on how to obtain reimbursement. This instruction includes the name of the reimbursing bank, an indication that the reimbursement is subject to the Uniform Rules for Bank-to-Bank Reimbursements Under Documentary Credits ('URR'), ICC Publication 525 and any additional information that affects the nominated bank's ability to receive reimbursement. Until recently, reimbursements were the subject of outline regulation by Article 19 of the Uniform Customs and Practice for Documentary Credits ('UCP') and national law. Now, however, the International Chamber of Commerce has drafted URR, designed to emulate the harmonization of rules governing documentary credits achieved by the UCP. The URR are complementary to the UCP, which they are not intended to override or change. They became effective on July 1, 1996. The purpose of this study is to promote understanding on the Uniform Rules for Bank-to-Bank Reimbursements under Documentary Credits. In this paper, I studied the following subjects:(1) Bank-to-Bank Reimbursements tranaction under Documentary Credits, (2) Meaning of the URR's promulgation, (3) Analysis on the URR's Article. (1) General provisions and definitions, (2) Liabilities and responsibilities, (3) Form and notification of authorisations, amendments and claims, (4) Miscellaneous provisions.

• 한국영양학회:학술대회논문집
• /
• 한국영양학회 2002년도 추계학술대회 및 총회
• /
• pp.88-88
• /
• 2002

• 무역상무연구
• /
• 제13권
• /
• pp.581-603
• /
• 2000

Beneficiary must present all documents stipulated in the Credit. If the documents conform in all respects with the terms and conditions of the Credit, beneficiary has a right to payment from an issuing or confirming bank. And banks must examine all documents presented by beneficiary for taking up the documents. If the documents appear on their face not to be in compliance with the terms and conditions of the Credit, banks may refuse to take up the documents. But standard for compliant documents with the terms and conditions of the Credit in the UCP or Section 5 of UCC is unclear. Because UCP Article 13(a) provides merely that banks must examine all documents stipulated in the Credit ${\cdots}$ to ascertain whether or not they appear, on their face, to be compliance with the terms and conditions of the Credit. ${\cdots}$ Documents which appear on their face to be inconsistent with one another will be considered as not appearing on their face to be in compliance with the terms and conditions of the Credit. Also UCC Section 5-108(a) provides merely that. ${\cdots}$ an issuer shall honor a presentation that, ${\cdots}$ appears on its face strictly to comply with the terms and conditions of the letter of credit. All problems are not resolve with easy by these regulations. Accordingly, I examined requirements for compliant documents with the terms and conditions of the Credit on the basis of the UCP and cases. To analyse this, I divided into three requirements ; (1) Completeness, (2) Regularity, (3) Linkage.

• 한방비만학회지
• /
• 제12권2호
• /
• pp.28-43
• /
• 2012

Objectives: The aim of the study was to investigate the efficacy of Boiogito for obesity. We examined the efficacy of Boiogito for obese patients and we expected the reaction of Boiogito would vary according to the single nucleotide polymorphism(SNPs). Methods: 111 subjects(body mass index${\geq}25m/kg^2$) were recruited and randomized to receive Boiogito(n=55) or Placebo(n=56) for 8weeks. Anthropometric factors, serum lipid profile, glucose, blood pressure(BP), pulse rate, resting metabolic rate and Korean version of obesity-related quality of life(KOQOL) scale measured at baseline and 8weeks. SNPs(${\beta}3$-adrenergic receptor(ADRB3), G protein ${\beta}3$(GNB3), peroxisome proliferator activated receptor gamma 2 gene(PPAR-${\gamma}2$), uncoupling protein(UCP2)) were conducted at baseline. Adverse reactions and safety outcome variables were also checked during trials. Results: Both groups showed significant improvement on obesity after treatment. Boiogito group decreased triglyceride than did control group and improved KOQOL. Boiogito showed a significant higher efficacy in C/T and T/T genotype of GNB3 gene / in Trp64 and Arg64 genotype of ADRB3 gene / in D/D genotype of UCP2 gene / in Pro/Pro genotype of PPAR-${\gamma}$ gene. Conclusions: Boiogito promoted obesity indexes without severe adverse reactions and proved its safety. Pharmacogenetical studies of Boiogito on obesity could be a effective method for the individualized treatment and prevention of obesity.

• Preventive Nutrition and Food Science
• /
• 제16권3호
• /
• pp.210-216
• /
• 2011

Capsaicin is a pungent component of red pepper, which is widely consumed as food adjuncts. The present study was performed to investigate anti-obesity effects of capsaicin in diet-induced obese rats. Male Sprague-Dawley rats (n=14) were fed with a high-fat diet (Control) or high-fat diet containing 0.016% capsaicin (w/w) (Capsaicin) for 8 weeks. The final body weight and the mass of white adipose tissue were significantly lower in capsaicin supplemented group compared to control. Dietary capsaicin ameliorated lipid profiles with decrease in the plasma concentrations of triglycerides and total cholesterol, and decrease in the levels of total lipids and triglycerides in the liver. Activity of glycerol-3-phosphate dehydrogenase (GPDH), an indicator of triglyceride biosynthesis in white adipose tissue, decreased by 35% in the group supplemented with capsaicin. However, consumption of capsaicin increased the expression of uncoupling protein 2 (UCP2) in white adipose tissue, which is related to energy consumption. Our data suggests that capsaicin may reduce body weight and fat accumulation in high fat diet-induced obese rats. These effects may be mediated, at least partially, by the upregulation of UCP2 gene expression and its ability to inhibit GPDH activity.

• Animal cells and systems
• /
• 제2권2호
• /
• pp.249-258
• /
• 1998

Obesity, one of the most common metabolic diseases in industrial countries is characterized by an increase in the number or size of adipocytes. In an effort to create transgenic mouse models for the study of obesity we developed a novel technique in which adipose tissue can be ablated genetically at will, at any specific developmental stage and/or physiological condition, by the treatment of ganciclovir. We made a series of adipocytespecific expression vectors using minimal regulatory regions of brown adipocyte-specific uncoupling protein (UCP-1) gene and adipocyte-specific aP2 gene, and then analyzed their expression characteristics in cultured cell lines. When both constructs pUCP-LacZ and paP2-LacZ were transfected transiently into differentiating 3T3-L1 (pre-while adipocytes) and HIB-1B (pre-brown adipocytes) cell lines in vitro and then monitored by X-gal staining of cells, these regulatory regions were sufficient to show proper differentiation stage-specific expression in adipocvtes. To confirm that adipocytes expressing HSV-TK controlled by these minimal requlatory elements are sufficient to kill themselves with ganciclovir treatment pUCP-TK and paP2-TK expression constructs were transfected stably into HIB-1B and 3T3-L1 cells, respectively, and their ganciclovir sensitivities were tested during in vitro differentiation of cells. As expected more than 80% of cells were dead by the 7th day of treatment with ganciclovir while negative control cells were not affected at all. The data suqqest that the constructed vectors are suitable for obtaining novel obese transqenic models based on a conditional genetic tissue ablation method.

• Molecules and Cells
• /
• 제38권8호
• /
• pp.741-741
• /
• 2015

• 한국영양학회:학술대회논문집
• /
• 한국영양학회 2004년도 춘계학술대회
• /
• pp.189-189
• /
• 2004